Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Phase 2

Terminated

• Conditions: Atrial Fibrillation
• Interventions: Biological: Canakinumab; Biological: Placebo

• Registration Number: NCT01805960
• Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary

The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF recurrences within 6 months after electrical cardioversion in patients with persistent AF.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-03-05
• Study First Submitted QC: 2013-03-05
• Study First Posted: 2013-03-06
• Study Start: 2013-06
• Primary Completion: 2016-12
• Study Completion: 2016-12
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-13
• Last Update Posted: 2017-02-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• EKG-documented AF
• Undergoing electrical cardioversion
• C-reactive protein ≥1.25mg/L
• Age ≥ 50 years, women need to be postmenopausal

Exclusion Criteria

• Undergoing urgent cardioversion because of medical instability

• AF persistence after cardioversion or AF recurrence before randomization

• Atrial flutter

• Severe renal failure (creatinine clearance <30 ml/min)

• Known active or recurrent hepatic disorder (including cirrhosis, hepatitis A, B or C, or Alanine transaminase/aspartate aminotransferase levels >3x ULN or total bilirubin >2x ULN)

• History of malignancy other than basal cell skin carcinoma

• Known intolerance or allergic reactions to canakinumab

• Use of amiodarone within the last 6 months

• Known HIV or any other immune compromised state including neutropenia or immunodeficiency

• History of ongoing, chronic or recurrent infectious disease

• History or evidence of active tuberculosis (TB) infection at Visit 1 or one of the risk factors for tuberculosis such as but not limited or exclusive to:

  • History of any of the following: residence in a congregate setting (e.g. jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g. injection or noninjection), health-care workers with unprotected exposure to patients who are at high risk of TB or patients with TB disease before the identification and correct airborne precautions of the patient.
  • Close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease within the last 12 months.
  • Evidence of tuberculosis infection, at Visit 1, determined as defined by local guidelines/ local medical practice (see also below for determination of tuberculosis status). If presence of tuberculosis is established then treatment (according to local guidelines) must have been completed prior to randomization. Completion of treatment is determined by local TB guidelines or in the absence of such guidelines the following has to be demonstrated: TB has been treated adequately with antibiotics, cure can be demonstrated, and risk factors resulting in TB exposure and contracting TB have been removed (e.g. the patient does not live anymore in high TB exposure setting).

• Patients on systemic corticosteroids or other anti-inflammatory drugs other than non-steroidal anti-inflammatory drugs

• Patients on any biological drug targeting the immune system

• Acute coronary syndrome or acute stroke within 3 months

• History of heart failure hospitalization within 3 months

• Planned major surgery including planned coronary artery bypass grafting

• Women of childbearing potential

• Live vaccinations within 3 months prior to the randomization visit (visit 2) or live vaccinations planned during the trial.

• Life expectancy <1 year

• Inability to comply with the study protocol

• Previously enrolled in CONVERT-AF

• Patients who have received an investigational drug or device within 30 days of first visit.

• History of alcohol and/or substance abuse that could interfere with the conduct of the trial

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Canakinumab	Canakinumab	1 s.c. injection of canakinumab 150mg directly after cardioversion
Placebo	Placebo	1 s.c. injection directly after cardioversion

Primary Outcome Measures

Name	Time	Method
Recurrence of atrial fibrillation	180 days

Secondary Outcome Measures

Name	Time	Method
Recurrence of atrial fibrillation	90 days
Time to first redo cardioversion	180 days
Change in plasma levels of C-reactive protein	180 days

Trial Locations

Locations (5)

Kantonsspital St. Gallen; 🇨🇭 St. Gallen, Switzerland

Department of Medicine, University Hospital; 🇨🇭 Basel, Switzerland

HUG Geneve; 🇨🇭 Geneve, Switzerland

University Heart Center Hamburg; 🇩🇪 Hamburg, Germany

CHUV Lausanne; 🇨🇭 Lausanne, Switzerland